Lyell Immunopharma To Present Two Abstracts Highlighting New Clinical And Translational Data From Phase 1/2 Clinical Trial Of Rondecabtagene Autoleucel For Treatment Of Aggressive LBCL At ASH 2025

Author: Benzinga Newsdesk | November 03, 2025 09:02am

Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translational data from the Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL314) for the treatment of aggressive large B-cell lymphoma (LBCL) will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. Ronde-cel is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate, currently in pivotal development for the treatment of LBCL, that is designed to increase complete response rates and prolong the duration of response as compared to approved CD19‑targeted CAR T-cell therapies. The FDA has granted ronde-cel Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the treatment of relapsed and/or refractory diffuse LBCL in the third- or later-line setting.

Posted In: LYEL